Deep Human Biology Learning (DHBL) is a unique approach to oncology & neurology research. Through cross-disciplinary collaboration, drug discovery is accelerated, leading to faster development of ...
LEADS® leverages system-level readouts to enable unbiased discovery while providing deep mechanistic insight. Sinopia has generated the largest metabolomics dataset characterizing a small-molecule ...
In this article, we examine ongoing challenges shaping target-based drug discovery and highlight how new technologies and ...
Discover how AI is revolutionizing RNA drug development in a new article published in Engineering. Learn about the potential ...
In the pharmaceutical discovery process, understanding a drug’s residence time—the duration a molecule remains bound to its ...
AI therapeutics company built on causal biology, today announced the publication of research in Nature Communications validating its POSH (Pooled Optical Screening in Human cells) platform. The study ...
Forbes contributors publish independent expert analyses and insights. Greg Licholai writes and teaches about innovation in healthcare. TxGNN is the first AI model specifically developed to identify ...
Frey is founder and chief innovation officer of Deep Genomics. In a time of relentless AI hype and mounting global economic uncertainty, the real winners will be those who think long-term. One of the ...
Morning Overview on MSN
AlphaFold rewired science, and 5 years later it’s still evolving
AlphaFold arrived as a technical moonshot that suddenly made protein structures feel like software rather than secrets of ...
Ola Engkvist is the Executive Director and Head of Molecular AI in Discovery Sciences within R&D at AstraZeneca (headquartered in Cambridge, UK). His team harnesses advanced computational technologies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback